Knight TherapeuticsのSMA 200
Knight TherapeuticsのSMA 200は何ですか。
Knight Therapeutics, Inc.のSMA 200はCAD$6 +5.48%です。
SMA 200の定義は何ですか。
SMA 200は、過去200日間の終値の非加重平均として計算された過去200日間の平均株価です。
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
TSXのセクタHealth CareにおけるSMA 200の企業と比べるKnight Therapeutics
Knight Therapeuticsは何をしますか。
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Bijuva for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with intact uterus; IMVEXXY to treat postmenopausal moderate to severe dyspareunia; IBSRELA for the treatment of irritable bowel syndrome with constipation in adults; TRELSTAR to treat advanced prostate cancer and for pain associated with endometriosis; ILUVIEN for the treatment of vision loss due to diabetic macular oedema; and NERLYNX to treat early-stage breast cancer. The company also provides Burinex, for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome; PROBUPHINE, to treat opioid addiction; and MOVANTIK for the treatment of opioid-induced constipation. In addition, it offers Vidaza to treat myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven to treat advanced or metastatic breast cancer; Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma; Ladevina to treat multiple myeloma; Zyvalix for metastatic prostate cancer; Karfib to treat relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; AmBisome and Cresemba to treat fungal infection; and Impavido for leishmaniasis. Further, the company provides Ursofalk to treat biliary cirrhosis; Salofalk for ulcerative colitis; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Knight Therapeuticsと類似のsma 200
- Propel Funeral PartnersのSMA 200はAUD$6 +4.69%です。
- Passat SAのSMA 200は€6 -20.28%です。
- China Railway Signal & CommunicationのSMA 200は¥6 -15.91%です。
- Zambeef Products PlcのSMA 200はGBX6 +1.61%です。
- Serve Robotics IncのSMA 200は$6 +18.35%です。
- Leverage Sha Etp 2070のSMA 200は€6 +6.83%です。
- Knight TherapeuticsのSMA 200はCAD$6 +5.48%です。
- Harbour Centre DevelopmentのSMA 200はHKD$6 -14.50%です。
- MeridianのSMA 200はAUD$6 +0.01%です。
- QIWI plcのSMA 200は$6 +0.00%です。
- Value8 NVのSMA 200は€6 -1.28%です。
- Far East HorizonのSMA 200はHKD$6 -6.02%です。
- Trilogiq SAのSMA 200は€6 +3.86%です。